HC Wainwright Issues Negative Estimate for Rezolute Earnings

Key Points

• HC Wainwright cut its Q2 2027 EPS estimate for Rezolute to a loss of $0.18 per share from a projected loss of $0.14, while retaining a Buy rating and a $10 price target.
• Rezolute reported a quarterly loss of $0.18 per share, slightly better than analysts’ consensus estimate of a $0.19 loss.
• Analyst sentiment is broadly positive: 12 analysts rate the stock Buy and two rate it Sell, giving it a consensus “Moderate Buy” rating and an average price target of $11.22.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - HC Wainwright dropped their Q2 2027 EPS estimates for Rezolute in a report released on Friday, November 6th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of ($0.18) for the quarter, down from their prior forecast of ($0.14). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Rezolute's current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Rezolute's Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.19) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.51) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at $1.30 EPS.

A number of other research firms also recently weighed in on RZLT. Citigroup restated a "market outperform" rating on shares of Rezolute in a research report on Thursday, October 15th. Citizens Jmp raised their price target on Rezolute from $11.00 to $15.00 and gave the company a "market outperform" rating in a report on Tuesday, October 6th. Lake Street Capital lifted their price objective on Rezolute from $9.00 to $12.00 and gave the stock a "buy" rating in a research report on Tuesday, October 6th. Zacks Research cut Rezolute from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 13th. Finally, Craig Hallum upgraded shares of Rezolute from a "hold" rating to a "buy" rating and upped their target price for the company from $4.00 to $7.00 in a research report on Tuesday, September 29th. Twelve analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.22.

Rezolute Trading Down 0.3%

Shares of RZLT opened at $3.87 on Tuesday. The business's fifty day moving average price is $4.12 and its two-hundred day moving average price is $3.91. Rezolute has a 52 week low of $1.07 and a 52 week high of $11.46.

Rezolute (NASDAQ:RZLT - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01.

Institutional Trading of Rezolute

Several institutional investors and hedge funds have recently made changes to their positions in RZLT. Jennison Associates LLC acquired a new position in shares of Rezolute in the 1st quarter valued at $10,489,000. Siren L.L.C. acquired a new stake in shares of Rezolute during the first quarter worth $10,151,000. Dimensional Fund Advisors LP grew its stake in shares of Rezolute by 273.7% during the first quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company's stock worth $1,617,000 after purchasing an additional 388,346 shares during the period. Knott David M Jr grew its stake in shares of Rezolute by 8.8% during the first quarter. Knott David M Jr now owns 370,000 shares of the company's stock worth $1,128,000 after purchasing an additional 30,000 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in Rezolute by 23.5% in the third quarter. Russell Investments Group Ltd. now owns 259,307 shares of the company's stock valued at $1,074,000 after purchasing an additional 49,263 shares during the last quarter. Institutional investors own 82.97% of the company's stock.

About Rezolute

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases involving abnormal insulin activity. The company's lead product candidate is RZ358, also known as ersodetug, an investigational monoclonal antibody designed to reduce the effects of excessive insulin by binding to an allosteric site on the insulin receptor.

RZ358 is being developed primarily for the treatment of congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin, causing potentially severe and recurrent hypoglycemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.